Cursaro et al. designed and synthesized a series of vanillyl-based hydroxamic acid HDACi targeting HDAC6 and HDAC8, which are key epigenetic regulators implicated in aggressive neural tumors such as neuroblastoma and glioblastoma. Here, HDAC8 is linked to neuroblastoma.